Carevive Systems, a cloud-based EHR-integrated cancer care planning software, announced the completion of a Series C equity investment of $18 million.
Philips Health Technology Ventures led the funding round with participation from Debiopharm Innovation Fund, OurCrowd’s digital health fund, Qure Ventures, HLM Venture Partners, LRVHealth, Cerner, and founder Madelyn Trupkin Herzfeld.
Bruno Lempernesse, CEO of Carevive, said: “The funds will allow Carevive to bring its software and analytics platform, which uniquely connects clinical data with patients’ real-world reported experiences, to even more clinicians, patients, life science companies, and payers.”
Carevive provides cancer patients with personalized cancer care plans that improve clinical outcomes and enable oncology practices to operate in emerging value-based payment models.
According to the company, the software collects and analyzes longitudinal data highlighting Real-World Evidence on the cancer patient experience. The data is then used to auto-generate unique, personalized care plans delivered to patients at each clinic visit by oncology physicians and nurses.
The software allows patients to report symptoms and receive an updated care plan in real-time with evidence-based instruction from their care team. Collectively, the Carevive Real- World Evidence dataset insights are used to drive care delivery and oncolytic drug use and are used by pharmaceutical companies to influence future drug development.
“We have been following Carevive’s development for some time,” said Allen Kamer, Managing Partner at Qure Ventures. “Carevive made significant progress in the last year, is now in dozens of hospitals around the US, and was selected by Pfizer as the first Patient-Reported Outcomes (PRO) challenge winner for Carevive PROmpt. We are excited by the company’s growth and the addition of Bruno, a veteran of the health and data analytics industry, to Carevive’s senior leadership team.”
Including the latest funding round Carevive Systems, raised over $25 million to date. Bruno Lempernesse said: “This financing will advance Carevive’s patient-centered mission to improve the way cancer care is delivered. I’m proud to be leading such an innovative company with committed industry-leading investors supporting us.”